Authors

Latest:

Dr. Mark W. Kieran on Dabrafenib in Pediatric Patients with BRAF V600-Mutant Disease

Mark W. Kieran, MD, PhD, director, pediatric medical neuro-oncology, institute physician associate professor of pediatrics, Harvard Medical School, discusses the first study of dabrafenib in pediatric patients with BRAF V600–mutant disease.

Marko Velimirovic, MD

Latest:

Circulating Tumor DNA Testing Shows Growing Potential for Clinical Utility in Breast Cancer

CtDNA will continue to gain importance in precision oncology as physicians continue to uncover the role and interplay of genomic alterations that promote tumor heterogeneity.

Markus Albertsmeier, MD

Latest:

Dr. Albertsmeier on Radiotherapy Improving the Local Control of Sarcoma

Markus Albertsmeier, MD, surgeon, Ludwig Maximilian University of Munich, discusses radiotherapy improving the local control for patients with sarcoma.

Markus Renschler, MD

Latest:

Dr. Renschler Discusses Updated Results of the MPACT Study

Markus Renschler, MD, vice president, global head, Hematology Oncology Medical Affairs at Celgene, discusses updated results of the MPACT study, which examined nab-paclitaxel plus gemcitabine vs gemcitabine for patients with metastatic pancreatic cancer.

Marsha Fahey

Latest:

Urology Practices Form Collaborative Partnerships With Specialty Pharmacy Providers

Novel formulations of specialty drugs have shifted the treatment of patients taking oncologic and biologic agents from infusion centers to the doctor's office.

Marshall Posner, MD

Latest:

Dr Posner on the Mechanism of Action of Danivatirsen in HNSCC

Marshall Posner, MD, discusses the mechanism of action of danvatirsen in recurrent and/or metastatic head and neck squamous cell carcinoma.

Marta E. Heilbrun, MD

Latest:

The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations

Researchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.

Martee Hensley, MD

Latest:

Dr. Martee Hensley on Trabectedin as a Treatment for Uterine Leiomyosarcoma

Martee Hensley, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the introduction of trabectedin into the armamentarium for uterine leiomyosarcoma. Hensley says the FDA approval for the treatment requires patients to have had a prior anthracycline therapy, and the treatment will likely fall into the third- or fourth-line of treatment for the malignancy. She adds that trabectedin may fall into the fourth-line due to treatments such as pazopanib currently occupying the third-line.

Martee L. Hensley, MD

Latest:

Dr. Hensley on dMRR and MSI-H Testing in Endometrial Cancer

Martee L. Hensley, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses DNA mismatch repair deficiency (dMMR) and microsatellite-instability high (MSI-H) testing for patients with endometrial cancer.

Martee L. Hensley, MD, Memorial Sloan Kettering Cancer Center

Martha L. Arellano, MD

Latest:

Dr. Arellano on Managing Older Patients With AML

Martha L. Arellano, MD, discusses the management of older patients with acute myeloid leukemia.

Martin Barrett, PhD

Latest:

Martin Barrett on Intravenous Versus Subcutaneous Rituximab

Martin Barrett, PhD, Clinical Scientist at Hoffmann-La Roche, discusses a study which compared intravenous (IV) rituximab to subcutaneous rituximab in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

Martin C. Tom, MD

Latest:

Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic Cancer

An integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.

Martin Dietrich, MD, PhD

Latest:

Unmet Needs in LCNEC

Panelists discuss what they would like to see in future trials to address the unmet needs and challenges in treating patients diagnosed with lung large cell neuroendocrine carcinoma (LCNEC).

Martin Dreyling, MD

Latest:

Dr Dreyling on the Potential for Chemotherapy-Free Treatments in MCL

Martin Dreyling, MD, discusses ongoing trials exploring chemotherapy-free strategies in mantle cell lymphoma using BTK inhibitors.

Martin E. Gutierrez, MD

Latest:

Dr. Gutierrez on the Investigation of MK-0482 in Advanced Solid Tumors

Martin E. Gutierrez, MD, discusses the investigation of MK-0482 in advanced solid tumors.

Martin Forster, MD

Latest:

Dr. Forster on Next Steps With Lurbinectedin in SCLC

Martin Forster, MD, a medical oncologist, University College London Hospitals, discusses the next steps with the investigational agent lurbinectedin in combination with doxorubicin as a second-line therapy for patients with small cell lung cancer (SCLC).

Martin Gutierrez, MD, Hackensack University Medical Center

Martin H. Voss, MD

Latest:

Dr Voss on the Evaluation of Nivolumab/Ipilimumab in Intermediate/Poor-Risk RCC

Martin H. Voss, MD, discusses the evaluation of nivolumab plus ipilimumab in IMDC-classified intermediate/poor-risk renal cell carcinoma.

Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center

Latest:

Dr Voss on the Clinical Significance of the KEYNOTE-564 Study in ccRCC

Martin H. Voss, MD, discusses the clinical significance of the phase 3 KEYNOTE-564 trial in clear cell renal cell carcinoma.